Home › Funds › Amundi US › GILD

Amundi US position in GILD

GILEAD SCIENCES INC · Health Care

Amundi US reported holding 11,259,657 shares of GILD (GILEAD SCIENCES INC) in its Q3 2026 13F filing — a position valued at US$1.68B, representing 0.39% of its reported portfolio and ranking #44 among its reported holdings. Amundi US has disclosed GILD holdings in 21 of the last 21 reported quarters, going back to Q3 2021.

Latest position (Q3 2026)11.26M sh
Reported value held$1.68B
Portfolio Weight0.39%
First reportedQ3 2021
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Amundi US's GILD position evolved

Amundi US first disclosed a stake in GILD in Q3 2021 at 10,443,516 shares (US$729.5M). The position peaked in Q3 2026 at 11,259,657 shares, worth US$1.68B. Across 21 filings, Amundi US increased the stake 11 time(s), trimmed it 8 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 11,259,657 shares valued at US$1.68B — an increase of 1,487,219 shares quarter over quarter.. Notable position changes include a 38% trim in Q1 2022 (shares rose 3% over the following quarter), a 34% trim in Q4 2024 (shares rose 21% over the following quarter), a 28% trim in Q3 2025 (shares rose 10% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2021 10.44M $729.46M New
Q4 2021 10.94M $788.10M Add
Q1 2022 6.82M $412.18M Reduce
Q2 2022 8.08M $499.65M Add
Q3 2022 10.21M $658.72M Add
Q4 2022 10.19M $885.69M Hold
Q1 2023 10.63M $887.55M Add
Q2 2023 10.92M $838.28M Add
Q3 2023 10.60M $817.83M Reduce
Q4 2023 10.52M $896.39M Reduce
Q1 2024 9.50M $640.29M Reduce
Q2 2024 11.24M $751.44M Add
Q3 2024 13.62M $1.16B Add
Q4 2024 9.02M $805.42M Reduce
Q1 2025 8.85M $994.99M Reduce
Q2 2025 10.47M $1.17B Add
Q3 2025 7.58M $861.37M Reduce
Q4 2025 9.52M $1.17B Add
Q1 2026 10.54M $1.47B Add
Q2 2026 9.77M $1.23B Reduce
Q3 2026 11.26M $1.68B Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About GILD and 13F data

GILD (GILEAD SCIENCES INC) is a Health Care company. 33 other funds we track also report a position in GILD — the largest reported positions include Fidelity Management & Research (FMR) (US$8.68B), Invesco Ltd (US$5.76B), Capital World Investors (US$5.36B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding GILD

All GILD fund holders →

FAQ

How long has Amundi US held GILD?

Amundi US has disclosed GILD holdings in 21 of the last 21 reported quarters, going back to Q3 2021.

What is Amundi US's current position in GILD?

As of Q3 2026, Amundi US holds 11.26M shares of GILD (GILEAD SCIENCES INC), valued at $1.68B, representing 0.39% of its reported portfolio and ranking #44.

Has Amundi US been buying or selling GILD?

In the latest 13F filing (Q3 2026), Amundi US increased its position in GILD. The position peaked in Q3 2026 at 11.26M shares.

Which other funds hold GILD?

Other major institutional holders of GILD include Fidelity Management & Research (FMR), Invesco Ltd, Capital World Investors, among 33 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.